Which has stronger valuation and earnings, COAG or SLN?

Hemab Therapeutics has higher earnings, but lower revenue than Silence Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Hemab Therapeutics N/A N/A N/A N/A N/A Silence Therapeutics $560K 772.71 -$88.61M -$1.59 N/A

Does the media favor COAG or SLN?

In the previous week, Hemab Therapeutics had 8 more articles in the media than Silence Therapeutics. MarketBeat recorded 13 mentions for Hemab Therapeutics and 5 mentions for Silence Therapeutics. Silence Therapeutics' average media sentiment score of 1.37 beat Hemab Therapeutics' score of 1.05 indicating that Silence Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hemab Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Silence Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor PAHC or SLN?

In the previous week, Silence Therapeutics had 2 more articles in the media than Phibro Animal Health. MarketBeat recorded 5 mentions for Silence Therapeutics and 3 mentions for Phibro Animal Health. Silence Therapeutics' average media sentiment score of 1.37 beat Phibro Animal Health's score of 0.77 indicating that Silence Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Phibro Animal Health 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Silence Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer SLN or XERS?

In the previous week, Silence Therapeutics had 4 more articles in the media than Xeris Biopharma. MarketBeat recorded 5 mentions for Silence Therapeutics and 1 mentions for Xeris Biopharma. Xeris Biopharma's average media sentiment score of 1.53 beat Silence Therapeutics' score of 1.37 indicating that Xeris Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Silence Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Xeris Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Silence Therapeutics (SLN) Competitors

$9.16 +1.89 (+26.00%)

Closing price 04:00 PM Eastern

Extended Trading

$9.20 +0.04 (+0.46%)

As of 07:59 PM Eastern

Compare

SLN vs. COAG, INBX, IMTX, PAHC, and XERS

Should you buy Silence Therapeutics stock or one of its competitors? MarketBeat compares Silence Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Silence Therapeutics include Hemab Therapeutics (COAG), Inhibrx Biosciences (INBX), Immatics (IMTX), Phibro Animal Health (PAHC), and Xeris Biopharma (XERS). These companies are all part of the "pharmaceutical products" industry.

How does Silence Therapeutics compare to Hemab Therapeutics?

Hemab Therapeutics (NASDAQ:COAG) and Silence Therapeutics (NASDAQ:SLN) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, valuation, profitability, analyst recommendations, risk, dividends and earnings.

98.7% of Silence Therapeutics shares are owned by institutional investors. 3.0% of Silence Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Hemab Therapeutics has higher earnings, but lower revenue than Silence Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hemab Therapeutics	N/A	N/A	N/A	N/A	N/A
Silence Therapeutics	$560K	772.71	-$88.61M	-$1.59	N/A

In the previous week, Hemab Therapeutics had 8 more articles in the media than Silence Therapeutics. MarketBeat recorded 13 mentions for Hemab Therapeutics and 5 mentions for Silence Therapeutics. Silence Therapeutics' average media sentiment score of 1.37 beat Hemab Therapeutics' score of 1.05 indicating that Silence Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hemab Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Silence Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Hemab Therapeutics has a net margin of 0.00% compared to Silence Therapeutics' net margin of -8,943.86%. Hemab Therapeutics' return on equity of 0.00% beat Silence Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hemab Therapeutics	N/A	N/A	N/A
Silence Therapeutics	-8,943.86%	-105.34%	-52.79%

Hemab Therapeutics currently has a consensus price target of $41.40, indicating a potential upside of 44.00%. Silence Therapeutics has a consensus price target of $55.00, indicating a potential upside of 500.44%. Given Silence Therapeutics' higher probable upside, analysts plainly believe Silence Therapeutics is more favorable than Hemab Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hemab Therapeutics	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83
Silence Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Summary

Silence Therapeutics beats Hemab Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Silence Therapeutics compare to Inhibrx Biosciences?

Inhibrx Biosciences (NASDAQ:INBX) and Silence Therapeutics (NASDAQ:SLN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, institutional ownership, profitability, media sentiment, risk and dividends.

Inhibrx Biosciences presently has a consensus price target of $150.00, indicating a potential upside of 57.73%. Silence Therapeutics has a consensus price target of $55.00, indicating a potential upside of 500.44%. Given Silence Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Silence Therapeutics is more favorable than Inhibrx Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibrx Biosciences	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.33
Silence Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Silence Therapeutics has lower revenue, but higher earnings than Inhibrx Biosciences. Inhibrx Biosciences is trading at a lower price-to-earnings ratio than Silence Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibrx Biosciences	$1.30M	1,073.17	-$140.05M	-$8.39	N/A
Silence Therapeutics	$560K	772.71	-$88.61M	-$1.59	N/A

Inhibrx Biosciences has a net margin of 0.00% compared to Silence Therapeutics' net margin of -8,943.86%. Silence Therapeutics' return on equity of -105.34% beat Inhibrx Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inhibrx Biosciences	N/A	-563.90%	-72.32%
Silence Therapeutics	-8,943.86%	-105.34%	-52.79%

82.5% of Inhibrx Biosciences shares are held by institutional investors. Comparatively, 98.7% of Silence Therapeutics shares are held by institutional investors. 18.3% of Inhibrx Biosciences shares are held by company insiders. Comparatively, 3.0% of Silence Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Silence Therapeutics had 5 more articles in the media than Inhibrx Biosciences. MarketBeat recorded 5 mentions for Silence Therapeutics and 0 mentions for Inhibrx Biosciences. Silence Therapeutics' average media sentiment score of 1.37 beat Inhibrx Biosciences' score of 0.00 indicating that Silence Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Inhibrx Biosciences	Neutral
Silence Therapeutics	Positive

Inhibrx Biosciences has a beta of 3.31, indicating that its share price is 231% more volatile than the broader market. Comparatively, Silence Therapeutics has a beta of 1.48, indicating that its share price is 48% more volatile than the broader market.

Summary

Silence Therapeutics beats Inhibrx Biosciences on 11 of the 16 factors compared between the two stocks.

How does Silence Therapeutics compare to Immatics?

Immatics (NASDAQ:IMTX) and Silence Therapeutics (NASDAQ:SLN) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, media sentiment, valuation and institutional ownership.

Silence Therapeutics has lower revenue, but higher earnings than Immatics. Silence Therapeutics is trading at a lower price-to-earnings ratio than Immatics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immatics	$54.60M	24.60	-$222.26M	-$1.99	N/A
Silence Therapeutics	$560K	772.71	-$88.61M	-$1.59	N/A

In the previous week, Silence Therapeutics had 5 more articles in the media than Immatics. MarketBeat recorded 5 mentions for Silence Therapeutics and 0 mentions for Immatics. Silence Therapeutics' average media sentiment score of 1.37 beat Immatics' score of 0.00 indicating that Silence Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Immatics	Neutral
Silence Therapeutics	Positive

64.4% of Immatics shares are owned by institutional investors. Comparatively, 98.7% of Silence Therapeutics shares are owned by institutional investors. 3.3% of Immatics shares are owned by company insiders. Comparatively, 3.0% of Silence Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Immatics presently has a consensus target price of $20.80, suggesting a potential upside of 107.58%. Silence Therapeutics has a consensus target price of $55.00, suggesting a potential upside of 500.44%. Given Silence Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Silence Therapeutics is more favorable than Immatics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immatics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Silence Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Immatics has a beta of 1.3, meaning that its stock price is 30% more volatile than the broader market. Comparatively, Silence Therapeutics has a beta of 1.48, meaning that its stock price is 48% more volatile than the broader market.

Immatics has a net margin of -572.35% compared to Silence Therapeutics' net margin of -8,943.86%. Immatics' return on equity of -47.36% beat Silence Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immatics	-572.35%	-47.36%	-39.35%
Silence Therapeutics	-8,943.86%	-105.34%	-52.79%

Summary

Silence Therapeutics beats Immatics on 10 of the 17 factors compared between the two stocks.

How does Silence Therapeutics compare to Phibro Animal Health?

Phibro Animal Health (NASDAQ:PAHC) and Silence Therapeutics (NASDAQ:SLN) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, profitability, earnings, institutional ownership and dividends.

99.3% of Phibro Animal Health shares are owned by institutional investors. Comparatively, 98.7% of Silence Therapeutics shares are owned by institutional investors. 50.1% of Phibro Animal Health shares are owned by insiders. Comparatively, 3.0% of Silence Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Phibro Animal Health has a net margin of 6.35% compared to Silence Therapeutics' net margin of -8,943.86%. Phibro Animal Health's return on equity of 37.14% beat Silence Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phibro Animal Health	6.35%	37.14%	8.57%
Silence Therapeutics	-8,943.86%	-105.34%	-52.79%

Phibro Animal Health currently has a consensus price target of $42.50, suggesting a potential upside of 35.52%. Silence Therapeutics has a consensus price target of $55.00, suggesting a potential upside of 500.44%. Given Silence Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Silence Therapeutics is more favorable than Phibro Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phibro Animal Health	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Silence Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Phibro Animal Health has a beta of 0.46, meaning that its share price is 54% less volatile than the broader market. Comparatively, Silence Therapeutics has a beta of 1.48, meaning that its share price is 48% more volatile than the broader market.

Phibro Animal Health has higher revenue and earnings than Silence Therapeutics. Silence Therapeutics is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phibro Animal Health	$1.30B	0.98	$48.26M	$2.33	13.46
Silence Therapeutics	$560K	772.71	-$88.61M	-$1.59	N/A

In the previous week, Silence Therapeutics had 2 more articles in the media than Phibro Animal Health. MarketBeat recorded 5 mentions for Silence Therapeutics and 3 mentions for Phibro Animal Health. Silence Therapeutics' average media sentiment score of 1.37 beat Phibro Animal Health's score of 0.77 indicating that Silence Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Phibro Animal Health	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Silence Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Phibro Animal Health beats Silence Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Silence Therapeutics compare to Xeris Biopharma?

Silence Therapeutics (NASDAQ:SLN) and Xeris Biopharma (NASDAQ:XERS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, dividends, risk, earnings, analyst recommendations and valuation.

Silence Therapeutics has a beta of 1.48, suggesting that its stock price is 48% more volatile than the broader market. Comparatively, Xeris Biopharma has a beta of 0.78, suggesting that its stock price is 22% less volatile than the broader market.

Silence Therapeutics currently has a consensus price target of $55.00, suggesting a potential upside of 500.44%. Xeris Biopharma has a consensus price target of $10.80, suggesting a potential upside of 45.95%. Given Silence Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Silence Therapeutics is more favorable than Xeris Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silence Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Xeris Biopharma	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Xeris Biopharma has a net margin of 3.81% compared to Silence Therapeutics' net margin of -8,943.86%. Xeris Biopharma's return on equity of 735.00% beat Silence Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silence Therapeutics	-8,943.86%	-105.34%	-52.79%
Xeris Biopharma	3.81%	735.00%	3.24%

98.7% of Silence Therapeutics shares are held by institutional investors. Comparatively, 42.8% of Xeris Biopharma shares are held by institutional investors. 3.0% of Silence Therapeutics shares are held by company insiders. Comparatively, 4.4% of Xeris Biopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Xeris Biopharma has higher revenue and earnings than Silence Therapeutics. Silence Therapeutics is trading at a lower price-to-earnings ratio than Xeris Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silence Therapeutics	$560K	772.71	-$88.61M	-$1.59	N/A
Xeris Biopharma	$291.85M	4.38	$550K	$0.06	123.33

In the previous week, Silence Therapeutics had 4 more articles in the media than Xeris Biopharma. MarketBeat recorded 5 mentions for Silence Therapeutics and 1 mentions for Xeris Biopharma. Xeris Biopharma's average media sentiment score of 1.53 beat Silence Therapeutics' score of 1.37 indicating that Xeris Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Silence Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Xeris Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Xeris Biopharma beats Silence Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Silence Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SLN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SLN vs. The Competition

Export

Metric	Silence Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$343.40M	$2.99B	$6.54B	$12.32B
Dividend Yield	N/A	1.78%	2.68%	5.88%
P/E Ratio	-5.76	18.65	25.39	23.96
Price / Sales	772.71	341.96	530.17	107.90
Price / Cash	N/A	56.64	45.29	53.76
Price / Book	6.94	4.14	10.76	6.41
Net Income	-$88.61M	$64.45M	$3.56B	$337.14M
7 Day Performance	35.50%	1.34%	1.37%	-0.48%
1 Month Performance	47.74%	0.95%	0.81%	0.49%
1 Year Performance	51.40%	24.33%	30.53%	28.16%

Silence Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SLN Silence Therapeutics	3.2185 of 5 stars	$9.16 +26.0%	$55.00 +500.4%	+26.0%	$343.40M	$560K	N/A	100	News Coverage Positive News Analyst Forecast Gap Up High Trading Volume
COAG Hemab Therapeutics	4.7934 of 5 stars	$29.20 -8.0%	$41.40 +41.8%	N/A	$1.36B	N/A	N/A	72	News Coverage Positive News
INBX Inhibrx Biosciences	2.0068 of 5 stars	$92.12 -1.3%	$150.00 +62.8%	+538.1%	$1.35B	$1.30M	N/A	166
IMTX Immatics	2.3723 of 5 stars	$9.91 +1.3%	$20.80 +109.9%	+83.2%	$1.33B	$54.60M	N/A	260	Positive News
PAHC Phibro Animal Health	4.9039 of 5 stars	$30.66 -1.3%	$42.50 +38.6%	+24.8%	$1.24B	$1.50B	13.16	2,475	Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SLN) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Silence Therapeutics (SLN) Competitors

SLN vs. COAG, INBX, IMTX, PAHC, and XERS

How does Silence Therapeutics compare to Hemab Therapeutics?

Summary

How does Silence Therapeutics compare to Inhibrx Biosciences?

Summary

How does Silence Therapeutics compare to Immatics?

Summary

How does Silence Therapeutics compare to Phibro Animal Health?

Summary

How does Silence Therapeutics compare to Xeris Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLN vs. The Competition

Silence Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Silence Therapeutics (SLN) Competitors

SLN vs. COAG, INBX, IMTX, PAHC, and XERS

How does Silence Therapeutics compare to Hemab Therapeutics?

Do institutionals and insiders have more ownership in COAG or SLN?

Which has stronger valuation and earnings, COAG or SLN?

Does the media favor COAG or SLN?

Is COAG or SLN more profitable?

Do analysts prefer COAG or SLN?

Summary

How does Silence Therapeutics compare to Inhibrx Biosciences?

Do analysts recommend INBX or SLN?

Which has preferable valuation & earnings, INBX or SLN?

Is INBX or SLN more profitable?

Do institutionals & insiders believe in INBX or SLN?

Does the media refer more to INBX or SLN?

Which has more volatility and risk, INBX or SLN?

Summary

How does Silence Therapeutics compare to Immatics?

Which has higher earnings and valuation, IMTX or SLN?

Does the media favor IMTX or SLN?

Do institutionals and insiders hold more shares of IMTX or SLN?

Do analysts recommend IMTX or SLN?

Which has more risk & volatility, IMTX or SLN?

Is IMTX or SLN more profitable?

Summary

How does Silence Therapeutics compare to Phibro Animal Health?

Do institutionals & insiders hold more shares of PAHC or SLN?

Is PAHC or SLN more profitable?

Do analysts recommend PAHC or SLN?

Which has more risk and volatility, PAHC or SLN?

Which has preferable valuation and earnings, PAHC or SLN?

Does the media favor PAHC or SLN?

Summary

How does Silence Therapeutics compare to Xeris Biopharma?

Which has more risk & volatility, SLN or XERS?

Do analysts recommend SLN or XERS?

Is SLN or XERS more profitable?

Do institutionals and insiders have more ownership in SLN or XERS?

Which has preferable valuation and earnings, SLN or XERS?

Does the media prefer SLN or XERS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLN vs. The Competition

Silence Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools